Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
JPEN J Parenter Enteral Nutr. 2023 May;47(4):550-562. doi: 10.1002/jpen.2498. Epub 2023 Apr 12.
With data demonstrating benefit, the prevalence of home enteral nutrition (HEN) has increased significantly over the last few decades. Despite this increase, there remains a paucity of data regarding real-world use of HEN including clinical outcomes and complications.
Descriptive analysis of prospectively maintained database of our specialized HEN program was undertaken. Patients who received care in our program with HEN initiation date between January 1, 2018, and December 31, 2020, were included in the analysis. Data regarding demographic information, anthropometrics, enteral nutrition (EN) regimen, electrolytes, and nutrition therapy history were included and tracked until July 31, 2021.
During the study period, 1600 patients initiated HEN treatment under our care. Majority of the study population needed EN therapy due to malignancy and its complications, including malignant dysphagia or mechanical obstruction (60.6%) followed by neurodegenerative diseases (7.5%). By the end of the study period, a majority of the patients (82%) stopped HEN treatment. Of these, 44.2% achieved EN goals and/or oral autonomy. Patients continued HEN treatment for a median of 100 (interquartile range, 32-301) days. Overall, 53.2% of patients experienced/reported at least one HEN-related complication that was clinically managed by the HEN team. Complications included tube-related, enteral feeding intolerance (EFI), and electrolyte shifts.
In our study population, HEN was most utilized to manage malignancy-related complications, including dysphagia. Unfortunately, complications, including EFI and tube-related complications, remained quite prevalent. Further evaluation regarding risk factors for complications and preventive mechanisms, such as increased education, is indicated.
随着数据显示其益处,家庭肠内营养(HEN)的流行在过去几十年中显著增加。尽管有这种增加,但关于 HEN 的实际使用,包括临床结果和并发症,仍然缺乏数据。
对我们专门的 HEN 计划的前瞻性维护数据库进行描述性分析。我们的计划中接受 HEN 起始日期在 2018 年 1 月 1 日至 2020 年 12 月 31 日之间的患者包括在分析中。纳入的数据包括人口统计学信息、人体测量学、肠内营养(EN)方案、电解质和营养治疗史,并一直跟踪到 2021 年 7 月 31 日。
在研究期间,1600 名患者在我们的护理下开始接受 HEN 治疗。研究人群中大多数需要 EN 治疗是由于恶性肿瘤及其并发症,包括恶性吞咽困难或机械性梗阻(60.6%),其次是神经退行性疾病(7.5%)。在研究结束时,大多数患者(82%)停止了 HEN 治疗。其中,44.2%的患者达到了 EN 目标和/或口服自主性。患者继续接受 HEN 治疗的中位数为 100 天(四分位距,32-301)。总体而言,53.2%的患者经历/报告了至少一种 HEN 相关并发症,这些并发症由 HEN 团队进行了临床管理。并发症包括与管相关的、肠内喂养不耐受(EFI)和电解质转移。
在我们的研究人群中,HEN 最常用于治疗与恶性肿瘤相关的并发症,包括吞咽困难。不幸的是,包括 EFI 和与管相关的并发症在内的并发症仍然相当普遍。需要进一步评估并发症的危险因素和预防机制,例如增加教育。